Search clinical trials for: 10 mg/kg Lpathomab

Total 2025 results

Lpath, Inc.

Completed

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

Healthy Subjects

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Eisai Inc.
Biogen

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
Firas El Chaer, MD

Recruiting

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

Hematologic Malignancy | Platelet Refractoriness

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
ReAlta Life Sciences, Inc.

Withdrawn

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

COVID-19 | Acute Lung Injury | ALI

United States
Novartis Pharmaceuticals

Completed

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Dry Eye

United States
Rezolute

Recruiting

RZ358 Treatment for Congenital Hyperinsulinism (sunRIZE)

Congenital Hyperinsulinism

Bulgaria, Canada, Denmark, France, Georgia, Germany, Greece, Israel, Oman, Qatar, Saudi Arabia, Spain, Turkey, United Arab Emirates, United Kingdom, Vietnam
Bill & Melinda Gates Medical Research Institute

Recruiting

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Malaria

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumor

China
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Novartis Pharmaceuticals

Completed

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, United Kingdom
Ludwig Institute for Cancer Research
Daiichi Sankyo Co., Ltd.; Austin Health

Completed

Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers (LUD2014-002)

Malignant Solid Tumor | Metastatic EphA2 Positive Cancer

Australia
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Rockefeller University
University of Cologne

Completed

A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074

Healthy | HIV

Germany, United States
Viridian Therapeutics, Inc.

Not yet recruiting

A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Thyroid Eye Disease

United States
Pfizer

Completed

A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Sweden
Alexion Pharmaceuticals

Terminated

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease (GIGVHD)

Acute Graft-Versus-Host Disease | GIGVHD

United States, France
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Alopexx Pharmaceuticals, LLC

Terminated

Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males

Neisseria Gonorrhoeae

United States
Merck KGaA, Darmstadt, Germany

Completed

Phase I/Ib Multiple Ascending Dose Study in China

Metastatic Solid Tumors

China
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Rockefeller University
Brigham and Women's Hospital; Weill Medical College of Cornell University; University...

Completed

A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

Healthy | HIV

United States, Germany
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
EA Pharma Co., Ltd.

Completed

A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
Viridian Therapeutics, Inc.

Recruiting

A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)

Thyroid Eye Disease

United States, Turkey
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Janssen Research & Development, LLC
Janssen Biologics BV

Completed

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

Ulcerative Colitis

United States, France, United Kingdom, Belgium, Switzerland, Israel, Canada, Australia, Netherlands, New Zealand, Austria, Germany, Denmark, Czechia, Argentina
Tunitas Therapeutics, Inc.
Tunitas Therapeutics Australia Pty Ltd

Terminated

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Allergy and Immunology

Australia
MedImmune LLC
PRA Health Sciences; Cambridge Antibody Technology

Terminated

A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma

Asthma

Netherlands, United Kingdom, Australia, Germany, Poland
NeuroVive Pharmaceutical AB

Completed

Copenhagen Head Injury Ciclosporin (CHIC) Study (CHIC)

Traumatic Brain Injury

Denmark
Naurex, Inc, an affiliate of Allergan plc

Completed

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

Major Depressive Disorder

United States
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies

Lupus Erythematosus, Discoid
Human Genome Sciences Inc.

Completed

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic

United States, Canada
Human Genome Sciences Inc.

Completed

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid

United States
Takeda

Completed

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

Neoplasms, Advanced Solid
Aptevo Therapeutics

Terminated

Phase 1b Safety and Efficacy Study of TRU-016

Chronic Lymphocytic Leukemia | Peripheral T-cell Lymphoma

United States
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)

Solid Tumors

Germany
Yale University
Heffter Research Institute; Ceruvia Lifesciences; CH TAC LLC

Completed

Psilocybin for the Treatment of Cluster Headache

Cluster Headache

United States
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

Systemic Lupus Erythematosus

United States
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (BLISS-76)

Systemic Lupus Erythematosus

United States, Spain, Israel, Netherlands, Canada, Germany, Poland, Romania, Puerto Rico, Costa Rica, Belgium, Slovakia, United Kingdom, Mexico, Italy, Austria, Czech Republic, Sweden, France
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
BioMarin Pharmaceutical

Completed

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Phenylketonuria

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Influenza

United States
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States

Search clinical trials for: 10 mg/kg Lpathomab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations